← Back to Search

Gallium Ga 68-labeled PSMA-11 for Prostate Cancer

Phase 1
Waitlist Available
Led By Maria Parayno
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 months
Awards & highlights

Study Summary

This trial is testing a new imaging technique to see if it can measure how well treatment is working for prostate cancer that has come back. The new technique uses a molecule that is found in abundance on most prostate cancer cells.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of adverse events

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (68GA-PSMA-11 PET)Experimental Treatment2 Interventions
Patients receive gallium Ga 68-labeled PSMA-11 IV over less than 1 minute, and then undergo PET over 60 minutes.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Positron Emission Tomography
2008
Completed Phase 2
~2240
Gallium Ga 68-labeled PSMA-11
2019
Completed Phase 2
~1030

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,660 Previous Clinical Trials
40,924,253 Total Patients Enrolled
561 Trials studying Prostate Cancer
507,095 Patients Enrolled for Prostate Cancer
City of Hope Medical CenterLead Sponsor
565 Previous Clinical Trials
1,921,441 Total Patients Enrolled
14 Trials studying Prostate Cancer
5,613 Patients Enrolled for Prostate Cancer
Maria ParaynoPrincipal InvestigatorCity of Hope Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer
2019. "68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04216134.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top